According to preliminary results reported Tuesday by Sobi and Selecta, 56% of patients in the U.S. Phase 3 test met the goal of achieving at least an 80% reduction in serum urate in month six.

Source: https://medcitynews.com/2023/03/sobi-and-selecta-bio-gout-drug-hits-phase-3-goals-paving-way-for-fda-submission/

Before I close and hand back to Guido, I would like to say thanks to everyone in Sobi who have helped advance science and care for people with rare and debilitating diseases.

Source: https://seekingalpha.com/article/4576626-swedish-orphan-biovitrum-ab-publ-biovf-q4-2022-earnings-call-transcript?source=feed_all_articles